MedTrace Logo

Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus

NCT00004643 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES: I. Evaluate the toxicity of cytarabine in patients with refractory systemic lupus erythematosus.

II. Evaluate objective disease parameters, including serum complement levels, anti-DNA antibody titers, sedimentation rate, and the systemic lupus activity measure in these patients.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

DRUG

cytarabine

Sponsors & Collaborators

Principal Investigators

  • Bruce Richardson · University of Michigan

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-02-28

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004643 on ClinicalTrials.gov